[go: up one dir, main page]

MX2016015389A - Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. - Google Patents

Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.

Info

Publication number
MX2016015389A
MX2016015389A MX2016015389A MX2016015389A MX2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A
Authority
MX
Mexico
Prior art keywords
human
cynomolgus
antibody
epsilon
cells
Prior art date
Application number
MX2016015389A
Other languages
English (en)
Inventor
Lifke Valeria
Offner Sonja
Moessner Ekkehard
Jaeger Christiane
Ritter Mirko
Platzer Josef
Tiefenthaler Georg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016015389A publication Critical patent/MX2016015389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un aspecto como se reporta en la presente es el uso de un método que comprende la etapa de inmunizar a un animal experimental tres veces con PBLs primarios de mono cinomolgo, por lo cual los PBLs enriquecen opcionalmente las células T sin utilizar PBLs humanos primarios como inmuógeno y sin utilizar un agente desnaturalizante para producir un anticuerpo de reacción cruzada humano-cinomolgo que se enlaza específicamente al CD3 épsilon humano de la SEQ ID NO: 02 y se enlaza específicamente a un polipéptido de la SEQ ID NO: 01, en donde el anticuerpo de reacción cruzada humano-cinomolgo se enlaza específicamente a las células T humanas y de mono cinomolgo, activa las células T humanas y no se enlaza al mismo epítopo que el anticuerpo OKT3, el anticuerpo UCHT1 y/o el anticuerpo SP34.
MX2016015389A 2014-05-28 2015-05-22 Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. MX2016015389A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14170140 2014-05-28
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (1)

Publication Number Publication Date
MX2016015389A true MX2016015389A (es) 2017-04-13

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015389A MX2016015389A (es) 2014-05-28 2015-05-22 Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.

Country Status (13)

Country Link
US (3) US20170233475A1 (es)
EP (2) EP3149041A1 (es)
JP (1) JP6738285B2 (es)
KR (1) KR20170003591A (es)
CN (1) CN106459201A (es)
AU (1) AU2015266077A1 (es)
BR (1) BR112016022819A2 (es)
CA (1) CA2942453A1 (es)
IL (1) IL247740A0 (es)
MX (1) MX2016015389A (es)
RU (1) RU2016151235A (es)
SG (1) SG11201609950YA (es)
WO (1) WO2015181098A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102850929B1 (ko) 2015-12-09 2025-08-27 에프. 호프만-라 로슈 아게 항-약물 항체의 형성을 감소시키기 위한 ii형 항-cd20 항체
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
AU2018276419A1 (en) 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
IL267567B2 (en) * 2016-12-22 2024-08-01 Daiichi Sankyo Co Ltd Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
US11319371B2 (en) * 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
KR102324568B1 (ko) 2017-06-21 2021-11-10 길리애드 사이언시즈, 인코포레이티드 HIV gp120 및 CD3을 표적화하는 다중특이적 항체
US12486325B2 (en) 2017-09-21 2025-12-02 WuXi Biologics Ireland Limited Anti-CD3epsilon antibodies
CA3074130A1 (en) * 2017-09-21 2019-03-28 WuXi Biologics Ireland Limited Novel anti-cd3epsilon antibodies
CN111417719B (zh) * 2017-11-30 2023-08-29 豪夫迈·罗氏有限公司 B细胞培养方法
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
JP7530299B2 (ja) 2018-05-24 2024-08-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３抗体及びその使用
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
CR20220594A (es) * 2020-05-27 2023-01-17 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
CA3189473A1 (en) * 2020-09-24 2022-03-31 Andreas Bultmann Novel human antibodies binding to human cd3 epsilon
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
WO2022204316A2 (en) * 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
TW202244059A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
US20230295310A1 (en) * 2022-03-20 2023-09-21 Abcellera Biologics Inc. CD3 T-Cell Engagers and Methods of Use
CN118922448A (zh) * 2022-03-22 2024-11-08 莫佛塞斯公司 Cd3特异性的去免疫抗体
EP4496631A1 (en) 2022-03-23 2025-01-29 F. Hoffmann-La Roche AG Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
TW202404637A (zh) 2022-04-13 2024-02-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
WO2005118635A2 (en) * 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
EP3770174A1 (en) * 2005-10-11 2021-01-27 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
NZ580746A (en) * 2007-04-03 2012-05-25 Micromet Ag Cross-species-specific bispecific binders
CN107903325B (zh) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
BR112013029893A2 (pt) * 2011-05-21 2017-05-30 Macrogenics Inc molécula de ligação a cd3, anticorpo de ligação a cd3, diacorpo de ligação a cd3 e composição farmacêutica
JP2017521998A (ja) * 2014-05-12 2017-08-10 ヌマブ アクチェンゲゼルシャフト 新規多重特異性分子及びかかる多重特異性分子に基づく新規治療方法

Also Published As

Publication number Publication date
JP6738285B2 (ja) 2020-08-12
SG11201609950YA (en) 2016-12-29
RU2016151235A3 (es) 2019-01-18
US20200299385A1 (en) 2020-09-24
IL247740A0 (en) 2016-11-30
EP3763739A1 (en) 2021-01-13
CA2942453A1 (en) 2015-12-03
AU2015266077A1 (en) 2016-09-29
RU2016151235A (ru) 2018-06-28
US20200325224A1 (en) 2020-10-15
KR20170003591A (ko) 2017-01-09
JP2017516786A (ja) 2017-06-22
US20170233475A1 (en) 2017-08-17
CN106459201A (zh) 2017-02-22
WO2015181098A1 (en) 2015-12-03
EP3149041A1 (en) 2017-04-05
BR112016022819A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
NZ762750A (en) Anti-hla-a2 antibodies and methods of using the same
IL317134A (en) An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ714516A (en) Human antibodies to clostridium difficile toxins
MX2022007774A (es) Anticuerpos de union a abril modificados.
NZ607969A (en) Cd33 binding agents
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
SG10201806293WA (en) Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
AR091605A1 (es) Proteinas de union anti-mesotelina
JP2017516786A5 (es)
MY202133A (en) Anti-sortilin antibodies and methods of use thereof
MX384246B (es) POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.
WO2013064700A3 (en) Chimeric human-camel antigens and their use
NZ759835A (en) Cd38 modulating antibody
PH12022550239A1 (en) Anti-ms4a4a antibodies and methods of use thereof